1.. Introduction {#S1}
================

Baclofen, a lipophilic derivative of γ-aminobutyric acid (GABA) with high blood brain barrier penetrance, acts as a selective agonist of the metabotropic GABA-B receptor (GABA~B~R). GABA~B~Rs are widely expressed throughout the central nervous system (CNS) at both pre-and post-synaptic terminals. Activation of GABA~B~Rs potentiates second messengers that, through desensitizing calcium channels and sensitizing potassium channels, hyperpolarizes the neuron to reduce neuronal excitability and inhibit neurotransmitter release ^[@R1]^. Therefore, GABA~B~R agonism has been considered as a potential therapeutic approach for disorders involving aberrant neuronal signaling. Baclofen is approved by the Food and Drug Administration (FDA) as a treatment for muscle spasticity. In addition to this approved indication, previous studies suggest that baclofen may represent a treatment for alcohol use disorder (AUD) ^[@R2]^

In rodent models, baclofen administration reduces alcohol intake and suppresses acquisition, maintenance, and reinstatement of alcohol seeking behavior ^[@R3]--[@R11]^. Administration of high doses of baclofen before alcohol presentation significantly increased alcohol consumption ^[@R12],\ [@R13]^, while operant conditioning studies show a decrease ^[@R14]--[@R18]^, or no change ^[@R19]^, in alcohol administration in rodents given moderate doses of baclofen. Preclinical data collectively suggest that alcohol seeking and consumption can be altered by baclofen administration, although the results vary across different studies, possibly due to differences in rodent strain, alcohol exposure, experimental paradigm, baclofen dosage, and other factors (for review, see: ^[@R20]^). In several human studies, treatment with baclofen (30 to 80 mg/d) reduced alcohol craving and drinking, and prolonged abstinence in alcohol-dependent individuals ^[@R21]--[@R25]^, while other studies employing similar dosing found no effect of baclofen on alcohol-related outcomes ^[@R26]--[@R29]^. Administering higher doses of baclofen has also produced mixed results: treatment with baclofen (up to 270 mg/d) improved abstinent rates in one study ^[@R30]^, but other studies found no difference between baclofen-(up to 180 mg/d) and placebo-treated individuals ^[@R31],\ [@R32]^. The results of three recent meta-analyses underscore the heterogeneity in effect sizes, enrolled populations, adjunct behavioral therapies, and baclofen doses in the previous studies ^[@R33]--[@R35]^, while the overall conclusion is that baclofen seems superior to placebo as a treatment for AUD.

Additional research is needed to understand the biobehavioral mechanisms underlying baclofen's function. Human laboratory paradigms pose an informative approach to examine the neurobiological and behavioral effects of medications ^[@R36]^, and a few studies have utilized this methodology to investigate how baclofen works in relation to alcohol use. In one experiment, baclofen, compared with cyproheptadine (as an active control), increased subjective ratings of stimulation and sedation, with no significant effect on cue-or alcohol-induced craving ^[@R37]^. Another study evaluating the effect of baclofen on alcohol cue-reactivity also found no significant effect on craving or attention to alcohol during the procedure ^[@R25]^. Evans and Bisaga (2009) reported that a single dose of baclofen, administered prior to a fixed-dose alcoholic beverage, increased alcohol sedation, with no effect on other subjective responses (*e.g.*, stimulation, drug liking) or alcohol-induced craving ^[@R38]^. Finally, in a recent human laboratory study, we found that baclofen significantly increased subjective effects of alcohol (*i.e.*, feeling high and intoxicated), and attenuated the positive association between post-priming breath alcohol concentration (BrAC) and the amount of alcohol self-administered ^[@R39]^. These findings suggest that baclofen's function, in relation to alcohol use, may be mediated through disrupting the link between an initial drink and subsequent alcohol consumption -- a hypothesis requiring further investigation.

To investigate baclofen's biobehavioral mechanisms of action, the present study examined whether and how baclofen may alter the relationship between alcohol-related parameters assessed in a well-controlled and ecologically valid laboratory setting, using data from our study cited above ^[@R39]^. In addition, while baclofen has been tested as a treatment for AUD for some years, most of the pharmacokinetic data come from studies in healthy individuals or those with neurological disorders. Considerable interindividual variability was found in the few studies that have assessed baclofen pharmacokinetics in alcohol-dependent individuals ^[@R40],\ [@R41]^, highlighting the need for more research in this regard. Therefore, we also characterized pharmacokinetic parameters of baclofen and examined whether these parameters correlate with alcohol-related behavioral measures in the laboratory.

2.. Materials and Methods {#S2}
=========================

2.1.. Participants and setting {#S3}
------------------------------

Potential candidates were first screened through a phone interview, followed by an in-person screening visit at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The study inclusion/exclusion criteria ([Appendix S1](#SD1){ref-type="supplementary-material"}) were assessed, and eligible individuals were enrolled after providing written informed consent. Non-treatment-seeking male and female individuals (21--65 years old) with a current diagnosis of alcohol dependence \[Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders -Fourth Edition -Text Revision (DSM-IV-TR) Axis I Disorders (SCID)\] and high trait anxiety \[Spielberger State Trait Anxiety Inventory (STAI) -trait version score ≥ 40\] were enrolled in this study. The protocol was approved by the NIH Addictions Institutional Review Board (IRB), and was registered at [ClinicalTrials.gov](https:ClinicalTrials.gov) (NCT01751386). Study visits were conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Alcohol administration procedures were performed consistent with the NIAAA Council Guidelines on Alcohol Administration (<https://www.niaaa.nih.gov/Resources/ResearchResources/job22.htm>). For a detailed description of the parent study, see: ^[@R39]^

2.2.. Design and procedures {#S4}
---------------------------

This was a between-subjects, randomized, double-blind, placebo-controlled human laboratory study. All procedures followed a predetermined timetable, as shown in [Figure 1](#F1){ref-type="fig"}. With an allocation ratio of 1:1, participants were randomized to receive oral racemic baclofen or placebo for one week in an outpatient setting. The initial dose of baclofen was 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose). After being on the target dose for at least 4 days, participants were brought back for an alcohol laboratory experiment ([Table S1](#SD1){ref-type="supplementary-material"}). The laboratory experiment was conducted during a full-day visit. Participants were asked to abstain from consuming alcohol 24 h prior to this visit and had to have a BrAC of 0 g/dL in the morning to proceed with the study procedures. They were also asked to take the first daily medication dose (10 mg) at home, before coming to the clinic. Standardized meals were served (400 kcal each, details in [Appendix S2](#SD1){ref-type="supplementary-material"}), and participants took the second daily medication dose (10 mg) at 11:00 am. This schedule was employed to allow participants receive the second dose of baclofen (or placebo) 1 h prior to the laboratory experiment, under direct observation of the research team. The laboratory experiment was conducted in a private bar-like room, included each participant's preferred alcoholic beverage, and consisted of three consecutive procedures: alcohol cue-reactivity (ACR), alcohol priming (AP), and alcohol self-administration (ASA), as outlined below and previously described ^[@R39],\ [@R42]^.

### 2.2.1.. Alcohol cue-reactivity (ACR): {#S5}

After an initial relaxation period, participants were exposed to a neutral beverage (water trial), followed by two consecutive alcohol trials. During each 3-minute trial, participants were asked to sniff the beverage upon hearing high tones and to stop sniffing upon hearing low tones. At the end of each trial, craving for alcohol was assessed via the alcohol urge questionnaire (AUQ). Cue-induced alcohol craving was calculated as follows: ∆ AUQ = \[½ (AUQ score post alcohol trial 1 + AUQ score post alcohol trial 2) -- AUQ score post water trial\].

### 2.2.2.. Alcohol priming (AP): {#S6}

The alcohol content of this priming drink was calculated based on each participant's total body water, to raise the blood alcohol concentration to 0.03 g/dL. The priming drink had to be consumed within 5 minutes. Participants rated their craving for alcohol, using the AUQ, and other subjective responses to alcohol, using the biphasic alcohol effects scale (BAES) and a modified drug effects questionnaire (DEQ). Assessments were performed at three time-points: 10, 30, and 40 minutes after AP. The highest rating among the three time-points for each variable was considered as the peak score. For more details about the instruments used, see [Appendix S3](#SD1){ref-type="supplementary-material"}.

### 2.2.3.. Alcohol self-administration (ASA): {#S7}

During a 2-hour session, participants were given the opportunity to self-administer up to 8 mini-drink *ad libitum*. As an alternative reinforcer, \$3.00 per mini-drink was provided for the ones not consumed. Each mini-drink was designed to raise the blood alcohol concentration by 0.015 g/dL. A safety limit of BrAC ≥ 0.12 g/dL was set, which would result in halting the session (this scenario did not happen during the present study). Total amount of alcohol self-administered was recorded as the primary outcome of this experiment, as reported in: ^[@R39]^

At the end of the laboratory experiment, participants were monitored until their BrAC reached 0 g/dL; they stayed in an inpatient unit and were discharged the following morning. Baclofen (or matched placebo) was continued for three additional days for safety reasons (5mg t.i.d., starting the evening after the laboratory session) ([Table S1](#SD1){ref-type="supplementary-material"}). The study was concluded with a brief follow-up visit, approximately one week after the laboratory experiment.

2.3.. Blood collection and processing {#S8}
-------------------------------------

At the beginning of the laboratory experiment visit, a saline lock intravenous catheter was inserted into the antecubital fossa of the non-dominant arm for multiple blood draws. Blood samples were collected at the following time-points ([Figure 1](#F1){ref-type="fig"} and [Table S2](#SD1){ref-type="supplementary-material"}): (T1) upon arrival, *i.e.*, approximately two hours after the first baclofen dose; (T2) 10 minutes after the ACR procedure, *i.e.*, approximately two hours after the second baclofen dose; (T3) 10 minutes after the priming drink was consumed; (T4) 10 minutes after the ASA session; and (T5) when participants' BrAC reached 0 g/dL. Prior to each visit, participants were asked to start fasting at midnight; therefore, the first blood draw (T1) was performed under fasting condition. A baseline (pre-drug) blood sample was also collected before dispensing baclofen or placebo (T0), which was not used for the present pharmacokinetic analyses. At each time-point, blood was collected into a lavender cap spray-coated K2EDTA tube (BD Vacutainer®) and centrifuged within 30 minutes post-collection (relative centrifugal force: 1700×g, temperature: 4 ^o^C, centrifugation time: 15 minutes). The extracted plasma was pipetted into microtubes and stored in a −80 ^o^C freezer until analysis. After completing the study and breaking the blind, blood samples collected from the baclofen-treated participants were used for pharmacokinetic measurements.

2.4.. Baclofen assay and quantification {#S9}
---------------------------------------

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed at the Clinical Pharmacokinetics Research Laboratory of the University of Rhode Island to quantify baclofen in the plasma samples obtained during this study. Briefly, the LC-MS/MS system consisted of an ACQUITY UPLC system, coupled to an API 3200 triple quadrupole mass spectrometer, equipped with an electrospray ionization source to detect positive ions in multiple reaction monitoring (MRM) mode. The following MRM transitions (precursor → product ion) were selected: m/z 214.2 → 151.3 for baclofen and m/z 218.9 → 155.3 for internal standard (IS). The method was validated according to the latest version of FDA guidance for industry on bioanalytical method validation ^[@R43]^. In order to extract baclofen from plasma for quantification, one part of plasma samples was mixed with three parts of IS solution in methanol (50 ng/mL). The mixtures were then centrifuged (10,000 ×*g* at 4 °C) for 10 min. Finally, 5 µL of the supernatant was withdrawn and injected into the LC-MS/MS system for quantification. For more details, see [Appendix S4](#SD1){ref-type="supplementary-material"}.

2.5. Statistical Methods {#S10}
------------------------

The parent study showed that baclofen, compared to placebo, had no significant main effect on the total amount of alcohol self-administered ^[@R39]^. In the present analyses, we examined whether baclofen modulated the relationship between ACR/AP (alcohol craving and other subjective responses to alcohol) and ASA (amount of alcohol consumed). Mixed effects models were used, with drug condition (baclofen vs. placebo) and each ACR/AP variable as fixed effects, participants as the random effect, and grams of alcohol consumed during ASA as the dependent variable. A total number of 9 variables were tested in individual models: ∆ AUQ during ACR, peak AUQ during AP, peak BAES (2 subscales) during AP, and peak DEQ (5 questions) during AP. As recommended by Bender and Lange ^[@R44]^, multiplicity adjustment was not performed for this exploratory/hypothesis-generating analysis. A list of potential covariates (age, gender, race, number of SCID criteria, average drinks per drinking days based on alcohol Timeline Followback 90 days prior to the screening visit, and peak BrAC during AP) were tested in the initial run of each model; significant covariates were retained in the final model analysis. Within the baclofen group, non-compartmental analysis (Phoenix WinNonlin, Pharsight Corp., Mountain View, CA -- Version 5.2.1) was used to characterize pharmacokinetic parameters of baclofen. As a marker of total drug exposure, the area under the plasma concentration-time curve (AUC) was determined and extrapolated to 16 h (the time of the first baclofen dose in the morning was considered as 0; see [Table S2](#SD1){ref-type="supplementary-material"}). Partial AUCs were also calculated, using the log-linear trapezoidal rule. Other estimated pharmacokinetic parameters were maximum plasma concentration (C~max~), the time of C~max~ (T~max~), half-life (t~1/2~), and apparent plasma clearance at steady state (CL~ss~/F). Finally, Pearson's correlation coefficients evaluated bivariate associations between baclofen's pharmacokinetic parameters (AUC and C~max~) and the laboratory behavioral variables (alcohol drinking, craving, and subjective responses). All data were examined for normal distribution and statistical outliers were removed prior to analysis. IBM SPSS Statistics for Windows (IBM Corp., Armonk, NY -- Version 20.0) was used for data analysis, and significance level was set at p \< 0.05 (two-tailed).

3.. Results {#S11}
===========

3.1.. Study sample {#S12}
------------------

A sample size of *N* = 34 was planned based on previous human laboratory studies (Cohen's *d* effect size: ≥ 0.5, power: 80%, two-tailed significance level: 0.05) ^[@R37],\ [@R45]^. To reach the target sample size, we randomized 39 individuals, and after 5 drop-outs, the final sample included 18 participants in the baclofen group and 16 participants in the placebo group ([Figure S1](#SD1){ref-type="supplementary-material"}). Baseline and demographic characteristics of the study sample are summarized in [Table S3](#SD1){ref-type="supplementary-material"}.

3.2.. Exposure-response analyses {#S13}
--------------------------------

### 3.2.1.. ACR-ASA: {#S14}

Baclofen did not affect the relationship between cue-induced alcohol craving during ACR and the amount of alcohol self-administered during ASA, as indicated by no significant drug × ∆ AUQ interaction effect on the grams of alcohol consumed (*F*~*1,8*~ = 1.85, *p* = 0.21).

### 3.2.2.. AP-ASA: {#S15}

There was a significant drug × peak AUQ interaction effect on the grams of alcohol consumed (*F*~*3,9*~ = 6.03, *p* = 0.01), where baclofen blunted the positive association between alcohol-induced craving during AP and the amount of alcohol self-administered during ASA ([Figure 2A](#F2){ref-type="fig"}). A significant drug × peak BAES 'sedation' effect was also detected (*F*~*3,6*~ = 8.37, *p* = 0.01) ([Figure 2B](#F2){ref-type="fig"}). Other alcohol-induced subjective measures showed a similar pattern, but the interaction terms did not reach statistical significance (*p*'s ≥ 0.05) ([Figure S2](#SD1){ref-type="supplementary-material"}).

3.3.. Pharmacokinetic parameters {#S16}
--------------------------------

Plasma concentrations of baclofen were measured in 17 individuals (14 males, 3 females); blood samples were not available for one participant in the baclofen group due to poor venous access. Pharmacokinetic parameters estimated for each participant are presented in [Table S4](#SD1){ref-type="supplementary-material"}, and the summary statistics are presented in [Table 1](#T1){ref-type="table"}.

3.4.. Pharmacokinetic-behavior correlations {#S17}
-------------------------------------------

There was a significant negative correlation between baclofen C~max~ and cue-induced alcohol craving during ACR (*r* = −0.57, *p* = 0.03) ([Figure 3A](#F3){ref-type="fig"}). In addition, baclofen C~max~ negatively correlated with peak DEQ 'like more' during AP (*r* = −0.57, *p* = 0.03) ([Figure 3B](#F3){ref-type="fig"}). No other significant correlations were found between baclofen pharmacokinetic parameters and the laboratory behavioral assessments (*p*'s ≥ 0.05) ([Table 2](#T2){ref-type="table"}).

4.. Discussion {#S18}
==============

We previously reported that baclofen, compared to placebo, did not significantly reduce alcohol craving or self-administration in this study. Baclofen, however, flattened the relationship between the peak BrAC during priming and subsequent alcohol self-administration, and amplified the effects of alcohol, *e.g.*, feeling high and intoxicated ^[@R39]^. The latter observation, *i.e.*, increased subjective response to alcohol after baclofen administration, is consistent with findings of the two human laboratory studies conducted before ^[@R37],\ [@R38]^. In the present set of analyses, we found that baclofen blunted the link between an initial alcohol priming and the amount of alcohol self-administration in a human laboratory setting. This pattern was observed for most of the AP variables, and statistically significant results were detected for alcohol-induced craving (assessed via AUQ) and sedation (assessed via BAES). To our knowledge, previous human laboratory studies did not report the effect of baclofen on the relationship between alcohol-related parameters, hence we cannot directly compare our findings with these studies. For this reason and given the exploratory/hypothesis-generating nature of this work, the results need to be confirmed in future studies. Nevertheless, the present data propose a biobehavioral mechanism through which baclofen acts, *i.e.*, by attenuating the effects of an initial drink on subsequent alcohol consumption. This interpretation was further corroborated by the finding that higher blood concentrations of baclofen (as indicated by baclofen C~max~) were associated with lower ratings of 'like more' on DEQ after consuming the priming drink (verbatim of the DEQ item: *would you like more of what you received, right now?*).

According to several lines of basic and clinical research, administering a priming dose of alcohol stimulates operant responding for alcohol and provokes alcohol seeking and consummatory behaviors -- a phenomenon known as the "alcohol priming effect". In rodent models, for example, priming injections of alcohol after a period of extinction leads to reinstatement of alcohol self-administration ^[@R46],\ [@R47]^; a similar priming effect has also been observed for other drugs of abuse ^[@R48]^. Interestingly, baclofen has been shown to block priming-induced reinstatement and escalation of drug use in numerous animal experiments ^[@R49]--[@R53]^. These preclinical observations are consistent with the present human findings where baclofen was found to disrupt the link between priming-induced effects and alcohol self-administration. Beyond baclofen, the present work is an example of the importance of human laboratory experiments in studying how medications affect alcohol-related outcomes -- an informative approach that may illuminate novel biobehavioral mechanisms of action compared to those classically seen with FDA-approved medications for AUD.

Evidence from human research further supports the notion that an initial low-to-moderate dose of alcohol increases subsequent alcohol consumption. A number of factors have been found to facilitate the aforementioned "alcohol priming effect", including (but not limited to) alcohol-induced craving and other subjective responses, interoceptive stimuli, attentional bias, alcohol expectancies, behavioral economic demand, and impaired control ^[@R54]--[@R59]^. A human laboratory study conducted by Christiansen and colleagues (2017) showed that priming with a placebo drink (that is 'believed' to contain alcohol, but does not), compared to a control drink (that is known to contain no alcohol), significantly increased craving, subjective intoxication, and *ad libitum* beer consumption ^[@R60]^. These findings suggest that anticipated effects of alcohol may play a more prominent role than its pharmacological effects *per se* in mediating the influence of a priming on alcohol-related outcomes. Consistent with this concept, the present study found that baclofen modulated the relationship between alcohol priming and self-administration without affecting alcohol pharmacokinetics, as indicated by no significant changes in BrAC ([Figure S3](#SD1){ref-type="supplementary-material"}).

Alcohol-induced craving and sedation are significant predictors of alcohol self-administration in human laboratory studies. Bujarski and colleagues (2018), for example, administered an initial dose of intravenous alcohol (alcohol challenge), followed by a progressive ratio self-administration, and found that craving and sedation during the alcohol challenge, respectively, predicted higher and lower alcohol self-administration ^[@R61]^. In our study, baclofen, as compared to placebo, blunted the positive association between alcohol-induced craving (during AP) and self-administration. In addition, while baclofen did not affect the relationship between cue-induced craving (during ACR) and self-administration, higher blood concentrations of baclofen (as indicated by baclofen C~max~) were associated with lower ratings of cue-induced craving. Craving is a prominent hallmark of addiction, and self-report measures of craving considerably correlate with objective measures of substance use, in both laboratory and naturalistic settings ^[@R54]^. From a neuroscientific perspective, craving is a multidimensional symptom with diverse biobehavioral substrates, and targeting craving may represent an effective approach to reduce alcohol drinking and/or to prevent relapse ^[@R62]--[@R64]^.

In addition to craving, we also found that baclofen, as compared to placebo, flattened the negative association between alcohol-induced sedation (during AP) and self-administration. Experiencing sedative effects typically leads to lower alcohol consumption, and Wardell and colleagues (2015) showed that alcohol-induced craving mediates this link ^[@R65]^. It has been well established that the level of sensitivity to alcohol effects plays a key role in shaping alcohol-related behaviors ^[@R66],\ [@R67]^. Accordingly, subjective response to alcohol may represent a targetable biobehavioral domain in the development of medications for AUD ^[@R36],\ [@R68]^. In the present study, we found that GABA~B~R agonism via baclofen altered the relationship between alcohol-induced subjective effects during AP and alcohol consumption during ASA ([Figure S2](#SD1){ref-type="supplementary-material"}). Our results also suggest that baclofen may be more efficacious in reducing alcohol drinking in those patients who experience higher craving and lower sedation after one drink (*i.e.*, priming). Contrary to Evans and Bisaga (2009) findings ^[@R38]^, baclofen did not increase sedation in this study. As previously discussed in: ^[@R39]^, methodological differences between the two studies (*e.g.* differences in the enrolled population, alcohol dosage, baclofen dosage, and length of baclofen administration) may explain, at least in part, these dissimilar results. It has been shown that GABA~B~Rs regulate alcohol sensitivity at the cellular/molecular level ^[@R69]--[@R72]^. Chronic alcohol exposure also leads to neuroadaptive changes in GABA~B~Rs ^[@R73],\ [@R74]^, which may further modulate the effects of baclofen in heavy-drinking alcohol-dependent individuals.

A causal role of GABA~B~Rs in alcohol reinforcement has been previously explained ^[@R75]--[@R77]^. It is also known that alcohol enhances GABAergic neurotransmission and, among other sites of action, activates GABA~A~Rs, which leads to hyperpolarization of the neurons through facilitating chloride influx into the cell ^[@R78],\ [@R79]^. Potentiation of GABA~B~Rs also hyperpolarizes neurons by increasing potassium and decreasing calcium permeability ^[@R1]^. It is therefore plausible to hypothesize that GABA~B~R agonism, in combination with alcohol, may pose an additive or synergistic effect on GABAergic neurons and decrease the amount of alcohol needed to have the same effect on GABAergic neurotransmission. While electrophysiological studies are required to directly test this hypothesis, our behavioral findings show that GABA~B~R agonism via baclofen modulates the response to an initial drink, such that subsequent drinking is less reinforcing. Accordingly, it has been suggested that baclofen may act as a partial substitution therapy by increasing subjective response to alcohol and mimicking alcohol's effects ^[@R37]--[@R39],\ [@R80]^. It appears that a certain level of alcohol drinking is required for baclofen to exert its optimal function -- a notion supported by previous findings that baclofen is more effective in heavy than light drinkers ^[@R34],\ [@R81]^. From a clinical perspective, it is crucial to identify subpopulations of patients who better respond to baclofen, *e.g.*, heavy-drinking alcohol-dependent individuals. Interestingly, a recent study in baboons showed that baclofen suppressed alcohol self-administration when the treatment was initiated during ongoing alcohol access, but not during alcohol abstinence ^[@R82]^. Baclofen may, therefore, serve as a harm reduction pharmacotherapy by helping heavy-drinking individuals reduce their alcohol consumption levels ^[@R83]^. Along these lines, the possibility of interaction between baclofen and alcohol should be further investigated in future studies.

Consistent with two previous reports in alcohol-dependent individuals ^[@R40],\ [@R41]^, we found considerable interindividual variability in baclofen pharmacokinetic parameters. In addition to other factors, this high variability may be partially responsible for the heterogeneity of response to baclofen and the inconsistency of previous reports. Our pharmacokinetic-behavior analyses provided a deeper insight into baclofen's effects on alcohol-related outcomes. For instance, baclofen was not superior to placebo in reducing cue-induced alcohol craving in our aggregate analyses ^[@R39]^, but here we found that higher blood concentrations of baclofen (C~max~) were associated with lower cue-induced alcohol craving during the ACR. These results suggest that, while all participants received the same dose of baclofen, interindividual variability in exposure to baclofen (resulting from pharmacokinetics variability) may have washed out the signal in the aggregate sample. Future studies should investigate whether individually tailored dosing versus fixed-dose treatment may be a better approach in the use of baclofen for AUD. In addition, the significant negative correlation between baclofen C~max~ and cue-induced craving suggests that doses higher than 30 mg/day may be needed to see an effect, particularly in AUD patients with no clinically significant liver impairment, as the sample enrolled in this study. 30 mg/day seems a sufficient dose of baclofen to reduce drinking in AUD patients with alcoholic liver disease (ALD) ^[@R22],\ [@R24]^, but higher doses may be needed in those without ALD. Nonetheless, additional pharmacokinetic studies with baclofen are required in the alcohol field, and such studies should be conducted in patients with and without ALD.

The results of this study should be viewed in the context of its limitations. The sample size was relatively small. A limited number of females were enrolled and, therefore, possible sex differences in behavioral outcomes and/or baclofen pharmacokinetics could not be studied. Participants could not self-administer more than eight mini-drinks, as the number was limited due to safety reasons. Only one dose of baclofen was used and, consequently, the effect of higher doses of baclofen on the reported outcomes remains unknown. Previous data suggests that the strength of alcohol priming effect varies by the dose of alcohol, as well as the time between priming and self-administration ^[@R84]^. Here, both the dosage and the timing were fixed, thus, the findings may not be generalizable to other experimental scenarios. Also, an alcoholic beverage was always used as the priming, and we did not run comparison sessions with placebo and/or control drinks; therefore, we cannot fully disentangle the pharmacological versus anticipated aspects of the priming effect. Finally, the finding of an effect of baclofen on the relationship between an initial drink and subsequent alcohol consumption was not an *a priori* hypothesis, and the present results should be further examined in prospective confirmatory studies.

In conclusion, our results suggest that GABA~B~R agonism via baclofen administration uncouples the link between an initial drink and subsequent alcohol consumption -- a potential biobehavioral mechanism of baclofen's effects on alcohol-related outcomes. In addition, considerable variability in pharmacokinetic measures is an important factor to take into account when employing baclofen as a treatment for AUD.
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![-- Schematic outline of the study procedures and assessments ^[@R1]^ Baclofen dosage was 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the laboratory experiment. For additional details, see [Table S1](#SD1){ref-type="supplementary-material"}.\
*Abbreviations:* **ACR**, Alcohol Cue-Reactivity; **AP**, Alcohol Priming; **ASA**, Alcohol Self-Administration; **AUQ**, Alcohol Urge Questionnaire; **BAES**, Biphasic Alcohol Effects Scale; **BrAC,** Breath Alcohol Concentration; **DEQ**, Drug Effects Questionnaire; **TX**, Treatment.](nihms-1508206-f0001){#F1}

![-- The effect of baclofen versus placebo on the relationship of (A) peak AUQ score and (B) peak BAES 'sedation' score during AP with the amount alcohol consumed during ASA. For other AP variables, see [Figure S2](#SD1){ref-type="supplementary-material"}.\
*Abbreviations:* **AP**, Alcohol Priming; **ASA**, Alcohol Self-Administration; **AUQ**, Alcohol Urge Questionnaire; **BAES**, Biphasic Alcohol Effects Scale.](nihms-1508206-f0002){#F2}

![-- Bivariate correlations between baclofen C~max~ and (A) ∆ AUQ score during ACR and (B) peak DEQ 'like more' score during AP.\
*Abbreviations:* **ACR**, Alcohol Cue-Reactivity; **AP**, Alcohol Priming; **AUQ**, Alcohol Urge Questionnaire; **C**~**max**~**,** Maximum Plasma Concentration; **DEQ**, Drug Effects Questionnaire.](nihms-1508206-f0003){#F3}

###### 

-- Pharmacokinetic parameters of baclofen estimated in individuals with alcohol dependence^[1](#TFN1){ref-type="table-fn"}^

  Parameter                                                       N    Mean       SD
  --------------------------------------------------------------- ---- ---------- ----------
  **AUC**~**0→16**~ (h\*ng/mL)^[2](#TFN2){ref-type="table-fn"}^   17   1033.50    403.14
  **AUC**~**0→4**~ (h\*ng/mL)                                     17   253.17     165.29
  **AUC**~**4→8**~ (h\*ng/mL)                                     17   446.50     169.53
  **AUC**~**8→12**~ (h\*ng/mL)                                    15   357.62     148.86
  **AUC**~**12→16**~ (h\*ng/mL)                                   15   221.30     145.16
  **C**~**max**~ (ng/mL)^[3](#TFN3){ref-type="table-fn"}^         14   84.90      50.84
  **t**~**1/2**~ (h)                                              11   4.42       0.98
  **CL**~**ss**~**/F** (mL/h)                                     17   60866.52   52123.17

Baclofen was administered in an outpatient setting (15 mg/day for 3 days, followed by 30 mg/day for at least 4 days). Blood samples for pharmacokinetic measurements were obtained on the day of the alcohol laboratory experiment, during which the first and the second daily medication doses (10 mg each) were respectively taken in the morning and one hour before the alcohol laboratory experiment started;

For AUC calculations, the time of the first baclofen dose in the morning was considered as 0 and extrapolated to 16 h (see [Table S2](#SD1){ref-type="supplementary-material"});

T~max~ data for each participant are presented in [Table S4](#SD1){ref-type="supplementary-material"} (Range: 2--4 h, Median: 2 h).

*Abbreviations:* **AUC**, Area Under the Plasma Concentration-Time Curve; **CL**~**ss**~**/F**, Apparent Plasma Clearance at Steady State; **C**~**max**~, Maximum Plasma Concentration; **N**, Number; **SD**, Standard Deviation; **T**~**max**~, Time of C~max~; **t**~**1/2**~, Half-Life.

###### 

-- Bivariate correlations between baclofen pharmacokinetic parameters and human laboratory behavioral assessments

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baclofen PK\                                  Laboratory Assessments^[1](#TFN5){ref-type="table-fn"}^                                                                          
  Parameter                                                                                                                                                                      
  --------------------------------------------- --------------------------------------------------------- ------- ------- ------- ------- ------- ------ ------- ------- ------- ------
  **AUC**~**0→16**~\                            ***r***                                                   -0.09   0.08    -0.10   -0.04   -0.13   0.15   0.17    -0.27   -0.40   0.23
  (h\*ng/mL)^[2](#TFN6){ref-type="table-fn"}^                                                                                                                                    

  ***p***                                       0.73                                                      0.74    0.69    0.86    0.60    0.56    0.49   0.28    0.10    0.36    

  **C**~**max**~\                               ***r***                                                   -0.57   -0.36   0.20    -0.25   -0.02   0.01   -0.57   -0.09   -0.16   0.05
  (ng/mL)                                                                                                                                                                        

  ***p***                                       0.03                                                      0.20    0.50    0.37    0.94    0.95    0.03   0.75    0.58    0.85    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

∆ AUQ was assessed during ACR. Grams of alcohol consumed was assessed during ASA. Other variables were assessed during AP;

The time of the first baclofen dose in the morning was considered as 0 and extrapolated to 16 h (see **Table S2**).

*Abbreviations:* **ACR**, Alcohol Cue-Reactivity; **AP**, Alcohol Priming; **ASA**, Alcohol Self-Administration; **AUC**, Area under the Plasma Concentration-Time Curve; **AUQ**, Alcohol Urge Questionnaire; **BAES**, Biphasic Alcohol Effects Scale; **C**~**max**~, Maximum Plasma Concentration; **DEQ**, Drug Effects Questionnaire; **PK**, Pharmacokinetic.
